PhaseBio Recruits BioVectra As Manufacturing Partner For Bentracimab

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has signed BioVectra as its manufacturing partner for its bentracimab as it ushers the drug through Phase 3.

• PhaseBio licensed bentracimab from AstraZeneca plc AZN, the maker of blood thinner Brilinta (ticagrelor), in 2017.
• It is a monoclonal antibody fragment that counters the effects of Brilinta by binding to the drug and its active metabolite.
• Under the deal, BioVectra will manufacture the active ingredient of bentracimab for use in those clinical trials and commercialization if it’s approved.
• Price Action: PHAS shares increased 2.6% at $4.17 in market trading hours on the last check Thursday.